The ASCO Post

The ASCO Post News and views from the world of clinical oncology and hematology

THE ASCO POST delivers timely and unbiased reports on major oncology meetings across the globe, including ASCO's annual meeting and regional symposia. Additionally, this newspaper-style publication provides readers with important summaries of evidence-based clinical literature from both general and specialty journals (fully sourced with links to original reports); notable research, data, and liter

ature with application in the clinic, including cost considerations/implications; columns from ASCO's membership with perspective on developments in oncology, quality cancer care, technology, electronic health records, and expert opinion on the state and economics of cancer care.

Avutometinib Plus Defactinib in Recurrent Low‑Grade Serous Ovarian Cancer
08/07/2025

Avutometinib Plus Defactinib in Recurrent Low‑Grade Serous Ovarian Cancer

The Leukemia & Lymphoma Society (LLS) is rebranding in advance of Blood Cancer Awareness Month in September.

Addition of Talazoparib to Enzalutamide in Metastatic CRPC in Genetically Unselected Cohort
08/01/2025

Addition of Talazoparib to Enzalutamide in Metastatic CRPC in Genetically Unselected Cohort

As reported in The Lancet by Agarwal et al, the final overall survival analysis of the phase III TALAPRO-2 trial showed that the addition of talazoparib to enzalutamide resulted in a significant benef...

ACS Study Finds Firefighters Face Increased Cancer Risk and Mortality
07/31/2025

ACS Study Finds Firefighters Face Increased Cancer Risk and Mortality

Being a firefighter increased the mortality risk for most cancers, especially for skin and kidney cancers, according to the results from a large prospective study by the American Cancer Society. Incre...

HER3-targeted patritumab deruxtecan shows efficacy in leptomeningeal metastases from solid tumors in Phase II TUXEDO-3 t...
07/28/2025

HER3-targeted patritumab deruxtecan shows efficacy in leptomeningeal metastases from solid tumors in Phase II TUXEDO-3 trial

The HER3-directed antibody-drug conjugate patritumab deruxtecan demonstrated clinical efficacy in treating patients with leptomeningeal metastatic disease of solid tumors, according to findings from a...

American Cancer Society Names New CEO
07/25/2025

American Cancer Society Names New CEO

“He is a bold, mission-driven leader with integrity and the proven ability to align purpose with performance. His leadership, passion, and deep belief in the urgency of our work will make a difference...

Corticosteroids May Limit Efficacy of Immunotherapy in Patients With NSCLC
07/23/2025

Corticosteroids May Limit Efficacy of Immunotherapy in Patients With NSCLC

“Steroids were the biggest predictor of why certain immunotherapies may not be effective, even when considering multiple other factors such as stage and progression of the disease,” said researchers.

Classifying Pancreatic Cysts Using AI Models
07/21/2025

Classifying Pancreatic Cysts Using AI Models

In a proof-of-concept study, researchers investigated whether artificial intelligence (AI) models such as ChatGPT-4 can be used to accurately extract and classify diagnostic data from radiologic imagi...

Mailed Self-Collection HPV Tests Improve Cervical Cancer Screening Rates
07/18/2025

Mailed Self-Collection HPV Tests Improve Cervical Cancer Screening Rates

Mail-in self-collection tests for human papillomavirus (HPV) more than doubled cervical cancer screening participation among never- and under-screened U.S. women, according to a first-of-its-kind stud...

“I Was Expecting to Hear I Have Heart Disease, Not Cancer”
07/16/2025

“I Was Expecting to Hear I Have Heart Disease, Not Cancer”

In 2022, I had a computed tomography (CT) coronary calcium scan to see whether there were any signs of narrowing or blockage in my heart arteries. Heart disease runs in my family. My father died of a ...

Silence Is Complicity
07/14/2025

Silence Is Complicity

On January 20, 2025, newly sworn-in President Donald J. Trump signed Executive Order 14151, “Ending Radical and Wasteful Government DEI Programs and Preferencing,”1 effectively eliminating all diversi...

Zanidatamab Plus Chemotherapy in Advanced HER2-Positive Gastroesophageal Adenocarcinoma
07/11/2025

Zanidatamab Plus Chemotherapy in Advanced HER2-Positive Gastroesophageal Adenocarcinoma

In a phase II trial reported in The Lancet Oncology, Elimova et al evaluated the efficacy and safety of zanidatamab plus chemotherapy in the first-line treatment of patients with advanced HER2-positiv...

Address

Huntington, NY

Alerts

Be the first to know and let us send you an email when The ASCO Post posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Share